AP1189

Phase 2Small molecule

SSynAct Pharma Aps

AP1189 is one of 72 small molecule programs targeting Joint Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Joint DiseaseActive, not recruiting

ProteinuriaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Joint DiseasePhase 2

Active, not recruiting

ProteinuriaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Simponi

19 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

AP1189

SSynAct Pharma Aps

Phase 2

3 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Completed·SSynAct Pharma Aps·Phase 2·NCT05604885·125 enrolled

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

Completed·SSynAct Pharma Aps·Phase 2·NCT05516979·127 enrolled

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

Recruiting·SSynAct Pharma Aps·Phase 2·NCT06671054·240 enrolled

Joint Disease1 trial

A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

Completed·SSynAct Pharma Aps·Phase 2·NCT04004429·105 enrolled

Proteinuria1 trial

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Recruiting·SSynAct Pharma Aps·Phase 2·NCT04456816·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AP1189. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP1189 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP1189. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SynAct Pharma Aps company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSynAct Pharma Aps

AP1189

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Joint Disease1 trial

Proteinuria1 trial

References

Drug Info

Quick Facts

Related News